Stay updated with breaking news from Mayo Stage. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Net cash used in operating and investing activities was $52.6 million in the fourth quarter and $136.7 million for the full year of 2023; quarter-end cash and restricted cash position was $621.0...
A panel of expert oncologists explore the ongoing AFFIRM-AL trial, examining birtamimab in patients diagnosed with Mayo stage IV AL amyloidosis.
Updates on PRX012 and PRX123 for treatment of Alzheimer’s disease, and on birtamimab for treatment of AL amyloidosis Remain on track with partnered programs: Bristol Myers Squibb , Roche and...
Net cash provided by operating and investing activities was $9.1 million in the third quarter and net cash used in operating and investing activities was $84.1 million for the first nine months of 2023; quarter-end cash and restricted cash position was $673.1 millionReceived $55 million payment from Bristol Myers Sq...
The addition of the chimeric monoclonal antibody CAEL-101 to standard therapy with cyclophosphamide, bortezomib, and dexamethasone with or without daratumumab demonstrated a manageable toxicity profile with prolonged clinical benefit in patients with amyloid light-chain amyloidosis.